Role of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and diabetic vascular dysfunction

PARP as a Therapeutic Target

Volumn , Issue , 2002, Pages 277-319

  Mabley, Jon G ^a   Virág, László ^a,b   Szabó, Csaba ^a  

^a INOTEK CORPORATION   (United States)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0012752950     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (205)

1. Atkinson, M. A. et al., Are insulin autoantibodies markers for insulin-dependent diabetes mellitus? Diabetes, 35, 894, 1986.
2. Kuglin, B., Gries, F. A., and Kolb, H., Evidence of IgG autoantibodies against human proinsulin in patients with IDDM before insulin treatment, Diabetes, 37, 130, 1988.
3. Baekkeskov, S. et al., Identification of the 64k autoantigen in insulin dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase (GAD), Nature, 347, 151, 1990.
4. Rerup, C. C., Drugs producing diabetes through damage of the insulin secreting cells, Pharmacol. Rev., 22, 485, 1970.
5. Rossini, A. A. et al., Studies of streptozotocin-induced insulitis and diabetes, Proc. Natl. Acad. Sci. U.S.A., 74, 2485, 1977.
6. Kolb, H., Mouse models of insulin dependent diabetes: low-dose streptozocin-induced diabetes and nonobese diabetic (NOD) mice, Diabetes Metab. Rev., 3, 751, 1987.
7. Bone, A. J., Lessons from animal diabetes, Diabet. Rev., 2, 11, 1993.
8. Prochazka, M., et al., 3 recessive loci required for insulin-dependent diabetes in nonobese diabetic mice, Science, 237, 286, 1987.
9. Lampeter, E. F. et al., Lessons from the NOD mouse for the pathogenesis and immunotherapy of human type 1 (insulin-dependent) diabetes mellitus, Diabetologia, 32, 703, 1989.
10. Mordes, J. P., Desemone, J., and Rossini, A. A., The BB rat, Diabetes Metab. Rev., 3, 725, 1987.
11. Kleemann, R. et al., Transcription and translation of inducible nitric oxide synthase in pancreas of prediabetic BB rats, FEBS Lett., 328, 9, 1993.
12. Suschek, C. et al., Primary cultures of rat islet capillary endothelial cells., Am. J. Path., 145, 685, 1994.
13. Southern, C., Schulster, D., and Green, I. C., Inhibition of insulin secretion by interleukin-1ß and tumour necrosis factor-alpha by an L-arginine-dependent nitric oxide generating mechanism, FEBS Lett., 276, 42, 1990.
14. Corbett, J. A. et al., Interleukin 1 beta induces the formation of nitric oxide by betacells purified from rodent islets of Langerhans. Evidence for the beta-cell as a source and site of action of nitric oxide, J. Clin. Invest., 90, 2384, 1992.
15. Flodstrom, M. et al., Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes, Diabetes, 48, 706, 1999.
16. Rabinovitch, A. et al., Inducible nitric oxide synthase (iNOS) in pancreatic islets of nonobese diabetic mice: identification of iNOS-expressing cells and relationships to cytokines expressed in the islets, Endocrinology, 137, 2093, 1996.
17. Suarez-Pinzon, W. L., Szabó, C., and Rabinovitch, A., Development of autoimmune diabetes in NOD mice is associated with the formation of peroxynitrite in pancreatic islet beta-cells, Diabetes, 46, 907, 1997.
18. Suarez-Pinzon, W. L. et al., Reduction of autoimmune diabetes in NOD mice by a selective inhibitor of the inducible nitric oxide synthase and scavenger of peroxynitrite. J. Autoimmunol., 16, 449, 2001.
19. G-monomethyl-L-arginine on the onset of diabetes in the spontaneously diabetic BB rat, Diabetes, 44, 360, 1995.
20. Corbett, J. A. et al., Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans, Proc. Natl. Acad. Sci. U.S.A., 90, 1731, 1993.
21. Eizirik, D. L. et al., Cytokines suppress human islet function irrespective of their effects on nitric oxide generation, J. Clin. Invest., 93, 1968, 1994.
22. Khatim, M. S. et al., Effect of recombinant IL-1 isomers on fetal and adult islet cell function and replication, Diabetes Res., 8, 25, 1988.
23. Green, I. C. et al., Effects of cytokines and nitric oxide donors on insulin secretion, cyclic GMP and DNA damage: relation to nitric oxide production, Biochem. Soc. Trans., 22, 30, 1994.
24. + depletion, Biochem. Biophys. Res. Commun., 199, 1270, 1994.
25. Fehsel, K. et al., Islet cell DNA is a target of inflammatory attack by nitric oxide, Diabetes, 42, 496, 1993.
26. Bolaffi, J. L. et al., Interrelationship of changes in islet nicotinamide adeninedinucleotide, insulin secretion, and cell viability induced by interleukin-1ß, Endocrinology, 134, 537, 1994.
27. Delaney, C. A. et al., Endogenous nitric oxide induced by interleukin-1ß in rat islets of Langerhans and HIT-T15 cells causes significant DNA damage as measured by the “comet” assay, FEBS Lett., 333, 291, 1993.
28. Delaney, C.A., et al., Cytokines induce deoxyribonucleic acid strand breaks and apoptosis in human pancreatic islet cells, Endocrinology, 138, 2610, 1997.
29. Kröncke, K.D., et al., Macrophage cytotoxicity towards isolated islet cells: neither lysis nor its protection by nicotinamide are beta-cell specific, Diabetologia, 34, 232, 1991.
30. Kaneto, H. et al., Apoptotic cell death triggered by nitric oxide in pancreatic β-cells, Diabetes, 44, 733, 1995.
31. Cunningham, J.M. et al., The effects on insulin secretion of agents which alter nitric oxide and cyclic GMP, Diabetologia, 35(Suppl 1), A128, 1992.
32. Eizirik, D. L. et al., Nitric oxide donors decrease the function and survival of human pancreatic islets, Mol. Cell. Endocrinol., 118, 71, 1996.
33. Hadjivassiliou, V. et al., Insulin secretion, DNA damage, and apoptosis in human and rat islets of Langerhans following exposure to nitric oxide, peroxynitrite, and cytokines, Nitric Oxide, 2, 429, 1998.
34. Heller, B. et al., Analysis of oxygen radical toxicity in pancreatic islets at the single cell level, Biol. Chem. Hoppe Seyler, 375, 597, 1994.
35. Uchigata, Y. et al., Protection by superoxide dismutase, catalase, and poly(ADP-ribose) synthetase inhibitors against alloxan- and streptozotocin-induced islet DNA strand breaks and against the inhibition of proinsulin synthesis, J. Biol. Chem., 257, 6084, 1982.
36. Szabó, C. and Dawson, V. L., Role of poly(ADP-ribose) synthetase in inflammation and ischaemia- reperfusion, Trends Pharmacol. Sci., 19, 287, 1998.
37. Schein, P. S., Cooney, D. A., and Vernon, M. L., The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumour activity, Cancer Res., 27, 2324, 1967.
38. Yamamoto, H. and Okamoto, H., Protection by picolinamide, a novel inhibitor of poly (ADP-ribose) synthetase, against both streptozotocin-induced depression of proinsulin synthesis and reduction of NAD content in pancreatic islets, Biochem. Biophys. Res. Commun., 95, 474, 1980.
39. Uchigata, Y. et al., Effect of poly(ADP-ribose) synthetase inhibitor administration to rats before and after injection of alloxan and streptozotocin on islet proinsulin synthesis, Diabetes, 32, 316, 1983.
40. Okamoto, H. and Yamamoto, H., DNA strand breaks and poly(ADP-ribose) synthetase activation in pancreatic islets - a new aspect to development of insulin-dependent diabetes and pancreatic β-cell tumors, Princess Takamatsu Symp., 13, 297, 1983.
41. Masiello, P. et al., Protective effect of 3-aminobenzamide, an inhibitor of poly(ADPribose) synthetase, against streptozotocin-induced diabetes, Diabetologia, 28, 683, 1985.
42. Masiello, P. et al., Protection by 3-aminobenzamide and nicotinamide against streptozotocin- induced beta-cell toxicity in vivo and in vitro, Res. Commun. Chem. Pathol. Pharmacol., 69, 17, 1990.
43. Shima, K. et al., Effect of poly(ADP-ribose) synthetase inhibitor administration to streptozotocin-induced diabetic rats on insulin and glucagon contents in their pancreas, Diabetes Res. Clin. Pract., 3, 135, 1987.
44. Bouix, O. et al., Protective effect of gamma-hydroxybutyrate and nicotinamide on low-dose streptozotocin-induced diabetes in mice, Horm. Metab. Res., 27, 216, 1995.
45. Mendola, J., Wright, J. R. J., and Lacy, P. E., Oxygen free-radical scavengers and immune destruction of murine islets in allograft rejection and multiple low-dose streptozocin- induced insulitis, Diabetes, 38, 379, 1989.
46. Soriano, G. F. et al., Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation, Nat. Med., 7, 108, 2001.
47. Yamada, K. et al., Preventative and therapeutic effects of large-dose nicotinamide injections and diabetes associated with insulitis - an observation in nonobese diabetic (NOD) mice, Diabetes, 31, 749, 1982.
48. Reddy, S., Bibby, N. J., and Elliott, R. B., Early nicotinamide treatment in the NOD mouse: effects on diabetes and insulitis suppression and autoantibody levels, Diabetes Res., 15, 95, 1990.
49. Nakajima, H. et al., Nicotinamide prevents the development of cyclophosphamide-induced diabetes mellitus in male non-obese diabetic (NOD) mice, Biomed. Res., 6, 185, 1985.
50. O’Brien, B. A. et al., Nicotinamide prevents the development of diabetes in the cyclophosphamide- induced NOD mouse model by reducing beta-cell apoptosis, J. Pathol., 191, 86, 2000.
51. Papaccio, G., Ammendola, E., and Pisanti, F. A., Nicotinamide decreases MHC class II but not MHC class I expression and increases intercellular adhesion molecule-1 structures in non-obese diabetic mouse pancreas, J. Endocrinol., 160, 389, 1999.
52. Szabo, C et al., Inhibition of poly(ADP-ribose) synthetase attenuates neutrophil recruitment and exerts antiinflammatory effects, J. Exp. Med., 186, 1041, 1997.
53. Kim, J. Y. et al., Inhibition of diabetes in non-obese diabetic mice by nicotinamide treatment for 5 weeks at the early age, J. Korean Med. Sci., 12, 293, 1997.
54. Augstein, P., et al., Apoptosis and beta-cell destruction in pancreatic islets of NOD mice with spontaneous and cyclophosphamide-accelerated diabetes, Diabetologia, 41, 1381, 1998.
55. O’Brien, B. A. et al., Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model, J. Pathol., 178, 176, 1996.
56. O’Brien, B. A. et al., Apoptosis is the mode of ß-cell death responsible for the development of IDDM in the nonobese diabetic (NOD) mouse, Diabetes, 46, 750, 1997.
57. Beales, P. E. et al., Diet can influence the ability of nicotinamide to prevent diabetes in the non-obese diabetic mouse: a preliminary study, Diabetes Metab. Res. Rev., 15, 21, 1999.
58. Hermitte, L. et al., High dose nicotinamide fails to prevent diabetes in BB rats, Autoimmunity, 5, 79, 1989.
59. Pan, J. et al., The effects of nicotinamide and glimepiride on diabetes prevention in BB rats, Life Sci., 57, 1525, 1995.
60. Wilson, G. L. et al., Mechanisms of nitrosourea-induced ß-cell damage - activation of poly(ADP-ribose) synthetase and cellular distribution, Diabetes, 37, 213, 1988.
61. Bolaffi, J. L., Nowlain, R. E., and Grodsky, G. M., Progressive damage of cultured pancreatic islets after single early exposure to streptozotocin, Diabetes, 35, 1027, 1986.
62. Sandler, S., Welsh, M., and Andersson, A., Streptozotocin-induced impairment of islet β-cell metabolism and its prevention by a hydroxyl radical scavenger and inhibitors of poly(ADP-ribose) synthetase, Acta Pharmacol. Toxicol., (Copenhagen), 53, 392, 1983.
63. Hoorens, A. and Pipeleers, D., Nicotinamide protects human beta cells against chemically- induced necrosis, but not against cytokine-induced apoptosis, Diabetologia, 42, 55, 1999.
64. Sandler, S., Welsh, M., and Andersson, A., Nicotinamide does not protect islet β-cell metabolism against alloxan toxicity, Diabetes, 33, 937, 1984.
65. Reddy, S., Salari-Lak, N., and Sandler, S., Long-term effects of nicotinamide-induced inhibiton of poly(adenosine diphosphate-ribose) polymerase activity in rat pancreatic islets exposed to interleukin-1ß, Endocrinology, 136, 1907, 1995.
66. Buscema, M. et al., Nicotinamide partially reverses the interleukin-1ß inhibition of glucose-induced insulin release in pancreatic islets, Metabolism, 41, 296, 1992.
67. Mabley, J. G. et al., Inhibition of poly(ADP-ribose) synthetase by gene disruption or inhibition with 5-iodo-6-amino-1,2-benzopyrone protects mice from multiple-lowdose- streptozotocin-induced diabetes, Brit. J. Pharmacol., 133, 909, 2001.
68. Andersen, H. U. et al., Nicotinamide prevents interleukin-1 effects on accumulated insulin release and nitric oxide production in rat islets of Langerhans, Diabetes, 43, 770, 1994.
69. Eizirik, D. L. et al., Nicotinamide decreases nitric oxide production and partially protects human pancreatic islets against the suppressive effects of combinations of cytokines, Autoimmunity, 19, 193, 1994.
70. Rabinovitch, A. et al., Human pancreatic islet beta-cell destruction by cytokines is independent of nitric oxide production, J. Clin. Endocrinol. Metab., 79, 1058, 1994.
71. Flodstrom, M., Welsh, N., and Eizirik, D., Cytokines activate the nuclear factor kappa B (NF-kappa B) and induce nitric oxide production in human pancreatic islets, FEBS Lett., 385, 4, 1996.
72. Oliver, F. J. et al., Resistance to endotoxic shock as a consequence of defective NFkappaB activation in poly(ADP-ribose) polymerase-1 deficient mice, EMBO J., 18, 4446, 1999.
73. Andrade, J. et al., Protection from nicotinamide inhibition of interleukin-1 beta-induced RIN cell nitric oxide formation is associated with induction of MnSOD enzyme activity, Endocrinology, 137, 4806, 1996.
74. Andersen, H. U. et al., Two-dimensional gel electrophoresis of rat islet proteins. Interleukin 1 beta-induced changes in protein expression are reduced by L-arginine depletion and nicotinamide, Diabetes, 44, 400, 1995.
75. Yamada, K., Ryu, E., and Nonaka, K., Protective effect of nicotinamide and 3- aminobenzamide on islet cell damage induced by gamma-interferon and tumor necrosis factor, Diabetes Res., 13, 85, 1990.
76. Kallman, B. et al., Toxicity of chemically generated nitric oxide towards pancreatic islet cells can be prevented by nicotinamide, Life Sci., 51, 671, 1992.
77. Burkart, V. et al., Oxygen radicals generated by the enzyme xanthine oxidase lyse rat pancreatic islet cells in vitro, Diabetologia, 35, 1028, 1992.
78. Radons, J. et al., Oxygen radicals induce ADP-ribose polymerization and NAD-depletion in isolated pancreatic islet cells, Diabetologia, 36(Suppl. 1), A61, 1993.
79. Kröncke, K. D. et al., Cytotoxicity of activated rat macrophages against syngeneic islet cells is arginine-dependent, correlates with citrulline and nitrite concentrations and is identical to lysis by the nitric oxide donor nitroprusside, Diabetologia, 36, 17, 1993.
80. Burkart, V. and Kolb, H., Protection of islet cells from inflammatory cell death in vitro, Clin. Exp. Immunol., 93, 273, 1993.
81. Pellat-Deceunynck, C., Wietzerbin, J., and Drapier, J. C., Nicotinamide inhibits nitric oxide synthase mRNA induction in activated macrophages, Biochem J., 297, 53, 1994.
82. Kretowski, A. et al., Nicotinamide inhibits enhanced in vitro production of interleukin-12 and tumour necrosis factor-alpha in peripheral whole blood of people at high risk of developing type 1 diabetes and people with newly diagnosed type 1 diabetes, Diabetes Res. Clin. Pract., 47, 81, 2000.
83. Sandler, S. and Andersson, A., Long-term effects of exposure of pancreatic islets to nicotinamide in vitro on DNA-synthesis, metabolism, and ß-cell function, Diabetologia, 29, 199, 1986.
84. Saldeen, J. and Welsh, N., Nicotinamide-induced apoptosis in insulin producing cells is associated with cleavage of poly(ADP-ribose) polymerase, Mol. Cell. Endocrinol., 139, 99, 1998.
85. Kolb, H. and Burkart, V., Nicotinamide in type 1 diabetes. Mechanism of action revisited, Diabetes Care, 22(Suppl. 2), B16, 1999.
86. Hauschildt, S., Scheipers, P., and Bessler, W. G., Inhibitors of poly(ADP-ribose) polymerase suppress lipopolysaccharide-induced nitrite formation in macrophages, Biochem. Biophys. Res. Commun., 179, 865, 1991.
87. Hauschildt, S. et al., Induction of nitric oxide synthase in L929 cells by tumor-necrosis factor a is prevented by inhibitors of poly(ADP-ribose) polymerase, Biochem. J., 288, 255, 1992.
88. Wilson, G. L. et al., Mechanisms of streptozotocin- and alloxan-induced damage in rat β cells, Diabetologia, 27, 587, 1984.
89. Szabó, C. et al., Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase, Proc. Natl. Acad. Sci. U.S.A., 95, 3867, 1998.
90. Heller, B. et al., Inactivation of the poly(ADP-ribose) polymerase gene affects oxygen radical and nitric oxide toxicity in islet cells, J. Biol. Chem., 270, 11176, 1995.
91. Wang, Z. Q. et al., Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease, Genes Dev., 9, 509, 1995.
92. Burkart, V. et al., Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin, Nat. Med., 5, 314, 1999.
93. Masutani, M. et al., Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes, Proc. Natl. Acad. Sci. U.S.A., 96, 2301, 1999.
94. Pieper, A. A. et al., Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes, Proc. Natl. Acad. Sci. U.S.A., 96, 3059, 1999.
95. Pozzilli, P., Browne, P., and Kolb, H., Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists, Diabetes Care, 19, 1357, 1996.
96. Elliott, R. B. and Chase, H. P., Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide, Diabetologia, 34, 362, 1991.
97. Elliott, R. B. et al., The use of nicotinamide in the prevention of type 1 diabetes, Ann. N.Y. Acad. Sci., 696, 333, 1993.
98. Mendola, G., Casamitjana, R., and Gomis, R., Effect of nicotinamide therapy upon ß-cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients, Diabetologia, 32, 160, 1989.
99. Pozzilli, P. et al., Nicotinamide increases C-peptide secretion in patients with recent onset type 1 diabetes, Diabetes Med., 6, 568, 1989.
100. Chase, H. P. et al., A trial of nicotinamide in newly diagnosed patients with type 1 (insulin- dependent) diabetes mellitus, Diabetologia, 33, 444, 1990.
101. Pozzilli, P. et al., Combination of nicotinamide and steroid versus nicotinamide in recent- onset IDDM. The IMDIAB II Study, Diabetes Care, 17, 897, 1994.
102. Pozzilli, P. et al., Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes (IMDIAB 1). The IMDIAB Study Group, Diabetes Med., 11, 98, 1994.
103. Visalli, N. et al., A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (the IMDIAB VI), Diabetes Metab. Res. Rev., 15, 181, 1999.
104. Vidal, J. et al., Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes, Diabetes Care, 23, 360, 2000.
105. Lampeter, E. F., Intervention with nicotinamide in pre-type 1 diabetes: the Deutsche Nikotinamid Interventions studie-DENIS, Diabetes Metab., 19, 105, 1993.
106. Lampeter, E. F. et al., The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group, Diabetes, 47, 980, 1998.
107. Gale, E. A. and Bingley, P. J., Can we prevent IDDM? Diabetes Care, 17, 339, 1994.
108. Polo, V., Saibene, A., and Pontiroli, A. E., Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas, Acta Diabetol., 35, 61, 1998.
109. Tooke, J. E. and Goh, K. L. Vascular function in Type 2 diabetes mellitus and pre-diabetes: the case for intrinsic endotheiopathy, Diabet. Med., 16, 710, 1999.
110. Keen, H., Clark, C., and Laakso, M., Reducing the burden of diabetes: managing cardiovascular disease, Diabetes Metab. Res. Rev., 15, 186, 1999.
111. De Vriese, A. S. et al., Endothelial dysfunction in diabetes, Br. J. Pharmacol., 130, 963, 2000.
112. Standl, E. and Schnell, O., A new look at the heart in diabetes mellitus: from ailing to failing, Diabetologia, 43, 1455, 2000.
113. Schaper, N. C., Nabuurs-Franssen, M. H., and Huijberts, M. S., Peripheral vascular disease and type 2 diabetes mellitus, Diabetes Metab. Res. Rev., 1, S11, 2000.
114. Furchgott, R. F., Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide, Biosci. Rep., 19, 235, 1999.
115. Ignarro, L. J., Nitric oxide: a unique endogenous signaling molecule in vascular biology, Biosci. Rep., 19, 51, 1999.
116. De Caterina, R., Endothelial dysfunctions: common denominators in vascular disease, Curr. Opin. Clin. Nutr. Metab. Care, 3, 453, 2000.
117. King, G. L., The role of hyperglycaemia and hyperinsulinaemia in causing vascular dysfunction in diabetes, Ann. Med., 28, 427, 1996.
118. Carter, A. M. and Grant, P. J., Vascular homeostasis, adhesion molecules, and macrovascular disease in non-insulin-dependent diabetes mellitus, Diabetes Med., 14, 423, 1997.
119. Giugliano, D., Ceriello, A., and Paolisso, G., Oxidative stress and diabetic vascular complications, Diabetes Care, 19, 257, 1996.
120. Cai, H. and Harrison, D. G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress, Circ. Res., 87, 840, 2000.
121. Honing, M. L. et al., Nitric oxide availability in diabetes mellitus, Diabetes Metab. Rev., 14, 241, 1998.
122. Lyall, F. et al., Increased nitrotyrosine in the diabetic placenta: evidence for oxidative stress, Diabetes Care, 21, 1753, 1998.
123. Chowienczyk, P. J. et al., Oral treatment with an antioxidant (raxofelast) reduces oxidative stress and improves endothelial function in men with type II diabetes, Diabetologia, 43, 974, 2000.
124. Laight, D. W., Carrier, M. J., and Anggard, E. E., Antioxidants, diabetes and endothelial dysfunction, Cardiovasc. Res., 47, 457, 2000.
125. Liu, S. S., Generating, partitioning, targeting and functioning of superoxide in mitochondria, Biosci. Rep., 17, 259, 1997.
126. Dionisi, O. et al., Superoxide radicals and hydrogen peroxide formation in mitochondria from normal and neoplastic tissues, Biochim. Biophys. Acta, 403, 292, 1975.
127. Poderoso, J. J. et al., Nitric oxide inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles, Arch. Biochem. Biophys., 328, 85, 1996.
128. Aso, Y. et al., Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes, Acta Diabetol., 37, 87, 2000.
129. Yamamoto Y. et al., Roles of the AGE-RAGE system in vascular injury in diabetes, Ann. N.Y. Acad. Sci., 902, 163, 2000.
130. Tesfamariam, B. et al., Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta, J. Cardiovasc. Pharmacol., 21, 205, 1993.
131. Diederich, D. et al., Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals, Am. J. Physiol., 266, H1153, 1994.
132. Angulo, J. et al., Impairment of nitric oxide-mediated relaxations in anaesthetized autoperfused streptozotocin-induced diabetic rats, Naunyn Schmiedebergs Arch. Pharmacol., 358, 529, 1998.
133. Rodriguez-Manas, L. et al., Endothelial dysfunction and metabolic control in streptozotocin- induced diabetic rats, Br. J. Pharmacol., 123, 1495, 1998.
134. Sakamoto, S. et al., Effect of exercise training and food restriction on endotheliumdependent relaxation in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous NIDDM, Diabetes, 47, 82, 1998.
135. Giugliano, D. et al., Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension, Diabetes Care, 21, 631, 1998.
136. Pieper, G., Dembny, K., and Siebeneich, W., Long-term treatment in vivo with NOX-101, a scavenger of nitric oxide, prevents diabetes-induced endothelial dysfunction, Diabetologia, 41, 1220, 1998.
137. Nishikawa, T. et al., Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage, Nature, 404, 787, 2000.
138. Pacher, P. et al., The role of poly(ADP-ribose) polymerase in the development of myocardial and endothelial dysfunction in diabetes mellitus, Diabetes, in press, 2002.
139. Soriano, F. G. et al., Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase, Circ Res, 89, 684, 2001.
140. Szabo, E. et al., Evidence for poly(ADP-ribose) polymerase activation in the diabetic retina, FASEB J., 15, A942, 2001.
141. Wahlberg, G. et al., Protective effect of nicotinamide against nephropathy in diabetic rats, Diabetes Res., 2, 307, 1985.
142. Wahlberg, G., Adamson, U., and Svensson, J., Pyridine nucleotides in glucose metabolism and diabetes: a review, Diabetes Metab. Res. Rev., 16: 33, 2000.
143. Bernard-Kargar, C. and Ktorza, A., Endocrine pancreas plasticity under physiological and pathological conditions, Diabetes, 50(Suppl. 1), S3, 2001.
144. Yonemura, Y. et al., Amelioration of diabetes mellitus in partially depancreatized rats by poly(ADP-ribose) synthetase inhibitors. Evidence of islet β-cell regeneration, Diabetes. 33, 401, 1984.
145. Yonemura, Y. et al., Induction of islet B-cell regeneration in partially pancreatectomized rats by poly(ADP-ribose) synthetase inhibitors, Int. J. Pancreatol., 3, 73, 1988.
146. Sugiyama, K., Yonemura, Y., and Okamoto, H., Effects of poly(ADP-ribose) synthetase inhibitor on β-cells of a canine pancreas after massive pancreatectomy, Int. J. Pancreatol., 8, 85, 1991.
147. Terazono, K. et al., A novel gene activated in regenerating islets, J. Biol. Chem., 263, 2111, 1988.
148. Okamoto, H., The Reg gene family and Reg proteins: with special attention to the regeneration of pancreatic beta-cells, J. Hepatobiliary Pancreat. Surg., 6, 254, 1999.
149. Anastasi, E. et al., Expression of Reg and cytokeratin 20 during ductal cell differentiation and proliferation in a mouse model of autoimmune diabetes, Eur. J. Endocrinol., 141, 644, 1999.
150. Gross, D. J. et al., Amelioration of diabetes in nonobese diabetic mice with advanced disease by linomide-induced immunoregulation combined with Reg protein treatment, Endocrinology, 139, 2369, 1998.
151. Yamaoka, T. et al., Diabetes and tumor formation in transgenic mice expressing Reg I, Biochem. Biophys. Res. Commun. 278, 368, 2000.
152. Kobayashi, S. et al., Identification of a receptor for reg (regenerating gene) protein, a pancreatic beta-cell regeneration factor, J. Biol. Chem., 275, 10723, 2000.
153. Akiyama, T. et al., Activation of Reg gene, a gene for insulin-producing beta-cell regeneration: poly(ADP-ribose) polymerase binds Reg promoter and regulates the transcription by autopoly(ADP-ribosyl)ation, Proc. Natl. Acad. Sci. U.S.A., 98, 48, 2001.
154. Miyamoto, T., Kakizawa, T., and Hashizume, K. Inhibition of nuclear receptor signalling by poly(ADP-ribose) polymerase, Mol. Cell. Biol., 19, 2644, 1999.
155. Simbulan-Rosenthal, C.M. et al., Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase, Proc. Natl. Acad. Sci. U.S.A., 97, 11274, 2000.
156. Garcia-Ocana, A. et al., Using beta-cell growth factors to enhance human pancreatic Islet transplantation, J. Clin. Endocrinol. Metab., 86, 984, 2001.
157. Kenyon, N.S. et al., Islet transplantation: present and future perspectives, Diabetes Metab. Rev., 14, 303, 1998.
158. Shapiro, A. M. et al., Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen, N. Engl. J. Med., 343, 230, 2000.
159. Sandler, S. and Andersson, A., Stimulation of cell replication in transplanted pancreatic islets by nicotinamide treatment, Transplantation, 46, 30, 1988.
160. Otonkoski, T. et al., Differentiation and maturation of porcine fetal islet cells in vitro and after transplantation, Transplantation, 68, 1674, 1999.
161. Otonkoski, T. et al., Nicotinamide and sodium butyrate for the induction of fetal porcine beta-cell differentiation prior to transplantation, Transplant. Proc., 29, 2045, 1997.
162. Kenmochi, T. et al., Protection of mouse islet isografts from early transplantation damage by nicotinamide treatment of recipients, Transplant. Proc., 26, 693, 1994.
163. Virág, L., The role of PARP in the immune system, in: Cell Death: The Role of PARP, Szabó C., Ed., CRC Press, Boca Raton, FL, 2000, pp. 31-166.
164. Marquet, R. L. et al., Primary nonfunction of islet xenografts: the role of macrophages, Transplant Int., 7, S660, 1994.
165. Nomikos, I. N. et al., Combined treatment with nicotinamide and desferrioxamine prevents islet allograft destruction in NOD mice, Diabetes, 35, 1302, 1986.
166. Suarez-Pinzon, W. L. et al., A potent poly(ADP-Ribose) synthase inhibitor protects against autoimmune diabetes in nonobese diabetic (NOD) mice, Annual Meeting of the Canadian Diabetes Association, (Suppl), 2001.
167. Szabó, C. et al., Regulation of components of the inflammatory response by 5-iodo-6-amino-1,2-benzopyrone, an inhibitor of poly(ADP-ribose) synthetase and pleiotropic modifier of cellular signal pathways, Int. J. Oncol., 10, 1093, 1997.
168. Roebuck, K. A. et al., H2O2 and tumor necrosis factor-alpha activate intercellular adhesion molecule 1 (ICAM-1) gene transcription through distinct cis-regulatory elements within the ICAM-1 promoter, J. Biol. Chem., 270, 18, 996, 1995.
169. Le Page, C., Sanceau, J., Drapier, J.C., and Wietzerbin, J., Inhibitors of ADP-ribosylation impair inducible nitric oxide synthase gene transcription through inhibition of NF kappa B activation, Biochem. Biophys. Res. Commun., 243, 451, 1998.
170. Pellat-Deceunynck, C., Wietzerbin, J., and Drapier, J. C., Nicotinamide inhibits nitric oxide synthase mRNA induction in activated macrophages, Biochem. J., 297, 53, 1994.
171. Zingarelli, B., Salzman, A. L., and Szabó, C., Genetic disruption of poly(ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury, Circ. Res., 83, 85, 1998.
172. Zingarelli, B., Szabó, C., and Salzman, A. L., Blockade of poly(ADP-ribose) synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in murine colitis, Gastroenterology, 116, 335, 1999.
173. Virág, L. et al., Cytoprotective effects of novel phenanthridinone inhibitors of poly(ADP-ribose) polymerase, FASEB J., 15, A567, 2001.
174. Szabó, É. et al., Peroxynitrite-induced poly(ADP-ribose) polymerase activation in keratinocytes: implications for contact hypersensitivity, J. Invest. Dermatol., 117, 74, 2001.
175. Cuzzocrea, S. et al., Beneficial effects of 3-aminobenzamide, an inhibitor of poly(ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion, Br. J. Pharmacol., 121, 1065, 1997.
176. Jijon, H. B. et al., Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis, Am. J. Physiol., 279, G641, 2000.
177. Cuzzocrea, S. et al., Protective effects of 3-aminobenzamide, an inhibitor of poly(ADP-ribose) synthase in a carrageenan-induced model of local inflammation, Eur. J. Pharmacol., 342, 67, 1998.
178. Liaudet, L. et al., Poly (ADP-ribose) synthetase mediates intestinal mucosal barrier dysfunction after mesenteric ischemia, Shock, 14, 134, 2000.
179. Amstad, P. A., Krupitza, G., and Cerutti, P. A., Mechanism of c-fos induction by active oxygen, Cancer Res., 52, 3952, 1992.
180. Akabane, A. et al., Nicotinamide inhibits IRF-1 mRNA induction and prevents IL-1 beta-induced nitric oxide synthase expression in pancreatic beta cells, Biochem. Biophys. Res. Commun., 215, 524, 1995.
181. Otsuka, A. et al., Nicotinamide and 3-aminobenzamide reduce interferon-gamma-induced class II MHC (HLA-DR and -DP) molecule expression on cultured human endothelial cells and fibroblasts, Immunopharmacol. Immunotoxicol., 13, 263, 1991.
182. Simbulan-Rosenthal, C. M. et al., Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase. Proc. Natl. Acad. Sci. U.S.A., 97, 11, 274, 2000.
183. Lyall, F. et al., Increased nitrotyrosine in the diabetic placenta: evidence for oxidative stress, Diabetes Care, 21, 1753, 1999.
184. Lorenzi, M. et al., High glucose induces DNA damage in cultured human endothelial cells. J. Clin. Invest., 77, 322, 1986.
185. Lorenzi, M. et al., Increased single strand breaks in DNA of lymphocytes from diabetic subjects, J. Clin. Invest., 79, 653, 1987.
186. Szabó, C. et al., Peroxynitrite causes energy depletion and increases permeability via activation of poly-ADP ribosyl synthetase in pulmonary epithelial cells, Am. J. Respir. Cell. Mol. Biol., 60, 105, 1997.
187. Kennedy, M. S., et al., Poly(ADP-ribose) synthetase mediates increased permeability induced by peroxynitrite in Caco-2BBE cells, Gastroenterology, 114, 510, 1998.
188. Ueda, K. and Hayaishi, O., ADP-ribosylation, Annu. Rev. Biochem., 54, 73, 1985.
189. Zhang, J. et al., Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity, Science, 263, 687, 1994.
190. Szabó, C. et al., Endothelial dysfunction in endotoxic shock: importance of the activation of poly(ADP ribose) synthetase by peroxynitrite, J. Clin. Invest., 100, 723-735, 1997.
191. Komjati, K. et al., Evidence for poly(ADP-ribose) polymerase activation in the human diabetic microvasculature, FASEB J., abstract, in press.
192. Oikawa, A. et al., Inhibitors of poly(adenosine diphosphate ribose) polymerase induce sister chromatid exchanges, Biochem. Biophys. Res. Commun., 97, 1311, 1980.
193. Simbulan-Rosenthal, C. M. et al., Chromosomal aberrations in PARP(-/-) mice: genome stabilization in immortalized cells by reintroduction of poly(ADP-ribose) polymerase cDNA, Proc. Natl. Acad. Sci. U.S.A., 96, 13, 191, 1999.
194. Smulson, M.E. et al., Roles of poly(ADP-ribosyl)ation and PARP in apoptosis, DNA repair, genomic stability and functions of p53 and E2F-1, Adv. Enzyme Regul., 40, 183, 2000.
195. Cleaver, J. E. and Morgan, W., 3-Aminobenzamide, an inhibitor of poly(ADP-ribose) polymerase, is a stimulator, not an inhibitor, of DNA repair, Exp. Cell. Res., 172, 258, 1987.
196. Borek, C. et al., Inhibition of malignant transformation in vitro by inhibitors of poly(ADP-ribose) synthesis, Proc. Natl. Acad. Sci. U.S.A., 81, 243-247, 1984.
197. Tsutsumi, M. et al., Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout mice to nitrosamine carcinogenicity, Carcinogenesis, 22, 1, 2001.
198. Conde, C. et al., Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice, EMBPO J., 20, 3535, 2001.
199. Tong, W. M., et al., DNA strand break-sensing molecule poly(ADP-ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression, Mol. Cell. Biol., 21, 4046, 2001.
200. + and poly(ADP-ribose) levels but do not affect diethylnitrosamine-induced altered hepatic foci in Fischer-344 rats, J. Nutr., 125, 1455, 1995.
201. Bryan, G. T., The influence of niacin and nicotinamide on in vivo carcinogenesis, Adv. Exp. Med. Biol., 206, 331, 1996.
202. Rakieten, N. et al., Modification of renal tumorigenic effect of streptozotocin by nicotinamide: spontaneous reversibility of streptozotocin diabetes, Proc. Soc. Exp. Biol. Med., 151, 356, 1976.
203. Hageman G. J. and Stierum, R. H., Niacin, poly(ADP-ribose) polymerase-1 and genomic stability, Mutat. Res., 475, 45, 2001.
204. Hageman, G. J. et al., Nicotinic acid supplementation: effects on niacin status, cytogenetic damage, and poly(ADP-ribosylation) in lymphocytes of smokers, Nutr. Cancer, 32,1 13, 1998.
205. Simbulan-Rosenthal, C. M. et al., Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy, Nucleic Acids Res., 29, 841, 2001.